Key developments in renin-angiotensin-aldosterone system inhibition.
about
Identification of hepta-histidine as a candidate drug for Huntington's disease by in silico-in vitro- in vivo-integrated screens of chemical librariesThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsNaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors and predicts thiazide sensitivity.Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.Hypotensive and sympathoinhibitory responses to selective central AT2 receptor stimulation in spontaneously hypertensive rats.International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Angiotensin-(1-7) Suppresses Hepatocellular Carcinoma Growth and Angiogenesis via Complex Interactions of Angiotensin II Type 1 Receptor, Angiotensin II Type 2 Receptor and Mas Receptor.Maintaining K+ balance on the low-Na+, high-K+ diet.The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness.Chronic angiotensin II infusion drives extensive aldosterone-independent epithelial Na+ channel activation.A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13AT1 antagonists: a patent review (2008 - 2012).Direct regulation of ENaC by bradykinin in the distal nephron. Implications for renal sodium handling.The renin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad.Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.The Role of the (Pro)renin Receptor in Hypertensive Disease.Future drug discovery in renin-angiotensin-aldosterone system intervention.Mega clinical trials which have shaped the RAS intervention clinical practice.The importance of non-HLA antibodies in transplantation.The adipose tissue and the involvement of the renin-angiotensin-aldosterone system in cardiometabolic syndrome.Novel Pathophysiological Mechanisms in Hypertension.Immunohistochemical expression of intrarenal renin angiotensin system components in response to tempol in rats fed a high salt diet.Raman micro-spectroscopy as a viable tool to monitor and estimate the ionic transport in epithelial cells.Effect of a stable Angiotensin-(1-7) analogue on progenitor cell recruitment and cardiovascular function post myocardial infarction.Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE?Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms.Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.Inhibitory effect of D3 dopamine receptor on migration of vascular smooth muscle cells induced by synergistic effect of angiotensin II and aldosterone.Bio-functional pickles that reduce blood pressure of rats.Diuretic Resistance.
P2860
Q28829351-C877D234-4BDF-4881-A8B1-188EDD4582C4Q30486707-69A487BD-D53E-43B7-974D-67F866A5BFF5Q33590418-20FB13E0-088A-4327-B750-0074C874930CQ34429685-4758EFB5-495E-4C57-9F7E-3C0D2DB3017FQ34458459-1B2A5A7D-8315-4445-A937-F368354E853BQ35601958-D0ECBAE0-75D5-40A1-AF99-D2C7E4889F93Q36241932-8DB2AC47-C55A-4E7A-BCAF-626F8E3BDCFFQ36307866-094F47EF-78DF-4E84-B92C-A36B853AEDE3Q36775665-71361CFB-779E-4E8F-9B03-024DCF9F2B63Q37261536-10B084E6-AC74-473F-8173-AD3605BB47E8Q37467721-92801673-086C-4174-98AC-B5399C1FE01CQ37738188-EB884916-50A4-4E8B-8150-3913C45DDCA4Q38130756-7EA28045-4A38-4679-B62C-65D166CEDCE3Q38174789-0EE2D479-C91B-421B-A1BC-792BE61447FAQ38176651-3EF6F183-82D2-44B8-9133-34B18BC6EA2FQ38248810-079AD828-B5AD-429F-AC14-0C24227339A9Q38428278-892330A5-208C-4831-8E9F-BA9307190743Q38679303-04C0649F-B834-47ED-97BE-3E724879486AQ38857792-0E2B9395-FE77-44F1-B123-10F04235639BQ38877375-7FC945BC-29FC-4D63-AF2C-F40B95C1A663Q38979226-51DC1A82-ADE6-44C6-BDEC-14D0A7C9F4D6Q39040850-AC0CDB1B-545F-43E6-8CD5-3D36A211D06DQ40805354-C51737BF-8E35-4D8F-84ED-528053E25AE0Q41821770-92F32F3B-9CCA-440F-9B84-890DF6FE692FQ43169811-A7042FC4-F53D-4BEA-AC6F-77F816F00DEEQ45915296-9F227E24-61E8-467E-9638-8CDB97264F10Q48008398-2BAEF9CA-E5CC-4341-9DD7-FB04B958D75CQ52598231-097E8BC3-737B-44F4-91FA-36DE80644472Q53671992-723EF9FB-5675-43F0-910F-AA24C4E4886EQ53753448-EC36638C-5C5F-4172-B889-59DBD6BE43E2Q53762226-927CBF14-A1CD-4F89-8DB8-9D1A6DF0411F
P2860
Key developments in renin-angiotensin-aldosterone system inhibition.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Key developments in renin-angiotensin-aldosterone system inhibition.
@en
type
label
Key developments in renin-angiotensin-aldosterone system inhibition.
@en
prefLabel
Key developments in renin-angiotensin-aldosterone system inhibition.
@en
P2093
P2860
P356
P1476
Key developments in renin-angiotensin-aldosterone system inhibition
@en
P2093
A H Jan Danser
Anton J M Roks
Ewout J Hoorn
Koen Verdonk
Nils van der Lubbe
P2860
P2888
P356
10.1038/NRNEPH.2012.249
P407
P577
2012-11-20T00:00:00Z